ClinicalTrials.gg
CompletedNCT00569946Updated Jun 5, 2019Results posted

Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)

A Phase 2 interventional study of AG-013736 in Carcinoma, Renal Cell, sponsored by Pfizer. Completed at 18 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-06-05.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing axitinib in Carcinoma, Renal Cell — 11 open to participants now, 15 under way, 1 of them phase 3. Axitinib · Carcinoma, Renal Cell.

Enrollment
12th of 41
64 · median 40
Started
2007
the only one that year
Phase 2
29 of 41
9 open now
Registered
2nd of 41
by date
Lead sponsor
6 of 41
Pfizer

Among the 41 studies testing axitinib in Carcinoma, Renal Cell, this one is the 12th largest by enrollment, is the only one that started in 2007, is one of 29 in phase 2, and was the 2nd registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

11 of the 41 studies testing axitinib in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About axitinib

Axitinib: first FDA approval 2012 (INLYTA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing axitinib in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

To investigate objective tumor response of AG-013736 for metastatic Renal Cell Cancer (mRCC)

03

Conditions studied

  • Carcinoma, Renal Cell

Keywords

  • AG-013736
  • RCC
  • Phase 2
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed as renal cell cancer with a component of clear cell cancer.
  • Patients who are to cytokine therapy as .
  • Patients who experienced nephrectomy.
  • Patients with at least 1 target lesion, as defined by .
  • Patients with no uncontrolled hypertension.

Exclusion criteria

Exclusion Criteria:

  • Gastrointestinal abnormalities
  • Current use or anticipated inability to avoid potent inhibitors or CYP1A2/3A4 inducers.
  • Active seizure disorder or evidence of .
  • Patients with hemoptysis.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    AG-013736

    Drug: AG-013736

Interventions

  • AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID. Number of cycles: until progression or unacceptable toxicity develops.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (Percentage of Participants With Complete Response [CR] or Partial Response [PR]): Independent Review Committee Assessment

    Percentage of participants with objective response based assessment of confirmed CR or confirmed PR by the Independent Review Committee, according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0). CR was defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks.

    Time frame: Up to 765 days of treatment at the data cut-off date

  2. Objective Response Rate (Percentage of Participants With Complete Response [CR] or Partial Response [PR]): Investigators Assessment

    Percentage of participants with objective response based assessment of confirmed CR or confirmed PR by the investigator, according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0). CR was defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks.

    Time frame: Up to 765 days of treatment at the data cut-off date

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Time in months from start of study treatment to first documentation of objective tumor progression or death due to any cause whichever comes first. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.44. Tumor progression was determined from radiological image (where data meet the criteria for progressive disease \[PD\]).

    Time frame: Up to 1709 days of treatment

  2. Time to Tumor Progression (TTP)

    Time in months from start of study treatment to first documentation of objective tumor progression. TTP was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.44. Tumor progression was determined from radiological image (where data meet the criteria for progressive disease \[PD\]).

    Time frame: Up to 1709 days of treatment

  3. Duration of Response

    Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.44. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

    Time frame: Start of first confirmed CR or PR to the date of the first event (PD or death) or the last tumor assessment, whichever came first, assessed up to 1709 days.

  4. Overall Survival (OS)

    OS was defined as the time from date of first dose of AG-013736 to date of death due to any cause. Subjects in whom death is not reported will have their event time censored on the last date the subject is known to be alive.

    Time frame: Up to 2002 days (maximum duration of treatment plus follow-up observation)

  5. Number of Participants Analyzed for Population Pharmacokinetics of AG-013736

    Population pharmacokinetic analysis of AG-013736 is conducted by combining current study data with other AG-013736 studies.

    Time frame: Cycle 1 Day 1 (2 hours after morning dose); Cycles 3, 5, and 7 Day 1 predose and 2 hours post morning dose

  6. Plasma Concentration of Soluble Vascular Endothelial Growth Factor Receptor 1 (s-VEGFR1)

    Time frame: Cycle 1 Day 1 predose, Day 1 of Cycle 2 to Cycle 7, and end of treatment/discontinuation (assessed up to 1709 days)

  7. Plasma Concentration of Soluble Vascular Endothelial Growth Factor Receptor 2 (s-VEGFR2)

    Time frame: Cycle 1 Day 1 predose, Day 1 of Cycle 2 to Cycle 7, and end of treatment/discontinuation (assessed up to 1709 days)

  8. Plasma Concentration of Soluble Vascular Endothelial Growth Factor Receptor 3 (s-VEGFR3)

    Time frame: Cycle 1 Day 1 predose, Day 1 of Cycle 2 to Cycle 7, and end of treatment/discontinuation (assessed up to 1709 days)

  9. Plasma Concentration of Soluble Stem Cell Factor Receptor (s-KIT)

    Time frame: Cycle 1 Day 1 predose, Day 1 of Cycle 2 to Cycle 7, and end of treatment/discontinuation (assessed up to 1709 days)

  10. Plasma Concentration of Vascular Endothelial Growth Factor (VEGF)

    Time frame: Cycle 1 Day 1 predose, Day 1 of Cycle 2 to Cycle 7, and end of treatment/discontinuation (assessed up to 1709 days)

  11. Number of Participants With Adverse Events

    Number of participants with any adverse events, adverse events graded as Common Terminology Criteria (CTCAE) for Adverse Events Version 3.0 Grade 3 or higher , serious adverse events, or adverse events resulted in discontinuation.

    Time frame: Up to 1709 days of treatment plus 28-days follow-up

07

Results

Posted Mar 27, 2012

Participant flow

Participant flow — Overall Study
MilestoneAG-013736
Started64
Completed5
Not completed59
Withdrew: Adverse event16
Withdrew: Objective progression or relapse42
Withdrew: Global deterioration of health status1

Outcome measures

PrimaryObjective Response Rate (Percentage of Participants With Complete Response [CR] or Partial Response [PR]): Independent Review Committee Assessment

Percentage of participants with objective response based assessment of confirmed CR or confirmed PR by the Independent Review Committee, according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0). CR was defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks.

Time frame:
Up to 765 days of treatment at the data cut-off date
Reported as:
Number · percentage of participants
Objective Response Rate (Percentage of Participants With Complete Response [CR] or Partial Response [PR]): Independent Review Committee Assessment
percentage of participantsAG-013736
Objective Response Rate (Percentage of Participants With Complete Response [CR] or Partial Response [PR]): Independent Review Committee Assessment50.0 (37.2 to 62.8)
PrimaryObjective Response Rate (Percentage of Participants With Complete Response [CR] or Partial Response [PR]): Investigators Assessment

Percentage of participants with objective response based assessment of confirmed CR or confirmed PR by the investigator, according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0). CR was defined as the disappearance of all target and nontarget lesions and no appearance of new lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters of the targeted lesions. CR and PR had to be documented on 2 occasions separated by at least 4 weeks.

Time frame:
Up to 765 days of treatment at the data cut-off date
Reported as:
Number · percentage of participants
Objective Response Rate (Percentage of Participants With Complete Response [CR] or Partial Response [PR]): Investigators Assessment
percentage of participantsAG-013736
Objective Response Rate (Percentage of Participants With Complete Response [CR] or Partial Response [PR]): Investigators Assessment54.7 (41.7 to 67.2)
SecondaryProgression-Free Survival (PFS)

Time in months from start of study treatment to first documentation of objective tumor progression or death due to any cause whichever comes first. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.44. Tumor progression was determined from radiological image (where data meet the criteria for progressive disease \[PD\]).

Time frame:
Up to 1709 days of treatment
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsAG-013736
Independent Review Committee Assessment11.0 (9.2 to 12.0)
Investigators Assessment12.0 (9.2 to 14.8)
SecondaryTime to Tumor Progression (TTP)

Time in months from start of study treatment to first documentation of objective tumor progression. TTP was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.44. Tumor progression was determined from radiological image (where data meet the criteria for progressive disease \[PD\]).

Time frame:
Up to 1709 days of treatment
Reported as:
Median · months
Time to Tumor Progression (TTP)
monthsAG-013736
Independent Review Committee Assessment11.0 (9.2 to 12.0)
Investigators Assessment12.0 (9.2 to 14.8)
SecondaryDuration of Response

Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.44. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Time frame:
Start of first confirmed CR or PR to the date of the first event (PD or death) or the last tumor assessment, whichever came first, assessed up to 1709 days.
Reported as:
Median · months
Duration of Response
monthsAG-013736
Independent Review Committee Assessment (n=33)11.1 (8.2 to 13.7)
Investigators Assessment (n=36)12.8 (7.7 to 17.5)
SecondaryOverall Survival (OS)

OS was defined as the time from date of first dose of AG-013736 to date of death due to any cause. Subjects in whom death is not reported will have their event time censored on the last date the subject is known to be alive.

Time frame:
Up to 2002 days (maximum duration of treatment plus follow-up observation)
Reported as:
Median · months
Overall Survival (OS)
monthsAG-013736
Overall Survival (OS)37.3 (28.6 to 49.9)
SecondaryNumber of Participants Analyzed for Population Pharmacokinetics of AG-013736

Population pharmacokinetic analysis of AG-013736 is conducted by combining current study data with other AG-013736 studies.

Time frame:
Cycle 1 Day 1 (2 hours after morning dose); Cycles 3, 5, and 7 Day 1 predose and 2 hours post morning dose

No measurements were reported for this outcome.

SecondaryPlasma Concentration of Soluble Vascular Endothelial Growth Factor Receptor 1 (s-VEGFR1)
Time frame:
Cycle 1 Day 1 predose, Day 1 of Cycle 2 to Cycle 7, and end of treatment/discontinuation (assessed up to 1709 days)
Reported as:
Median · pg/mL
Plasma Concentration of Soluble Vascular Endothelial Growth Factor Receptor 1 (s-VEGFR1)
pg/mLAG-013736
Cycle 1 Day 1 (n=64)83.10 (44.3 to 215)
Cycle 2 Day 1 (n=63)63.60 (0 to 190)
Cycle 3 Day 1 (n=60)68.20 (36.4 to 936)
Cycle 4 Day 1 (n=59)69.20 (33.5 to 119)
Cycle 5 Day 1 (n=57)62.90 (0 to 125)
Cycle 6 Day 1 (n=52)62.00 (32.1 to 119)
Cycle 7 Day 1 (n=48)57.75 (0 to 101)
End of Treatment/Discontinuation (n=55)76.60 (0 to 2780)
SecondaryPlasma Concentration of Soluble Vascular Endothelial Growth Factor Receptor 2 (s-VEGFR2)
Time frame:
Cycle 1 Day 1 predose, Day 1 of Cycle 2 to Cycle 7, and end of treatment/discontinuation (assessed up to 1709 days)
Reported as:
Median · pg/mL
Plasma Concentration of Soluble Vascular Endothelial Growth Factor Receptor 2 (s-VEGFR2)
pg/mLAG-013736
Cycle 1 Day 1 (n=64)8900.0 (2620 to 13400)
Cycle 2 Day 1 (n=63)6040.0 (2760 to 12600)
Cycle 3 Day 1 (n=60)5980.0 (3340 to 11600)
Cycle 4 Day 1 (n=59)6030.0 (3310 to 11600)
Cycle 5 Day 1 (n=57)5880.0 (3140 to 10400)
Cycle 6 Day 1 (n=52)5790.0 (3160 to 9920)
Cycle 7 Day 1 (n=48)5395.0 (3620 to 10400)
End of Treatment/Discontinuation (n=55)6540.0 (2870 to 12600)
SecondaryPlasma Concentration of Soluble Vascular Endothelial Growth Factor Receptor 3 (s-VEGFR3)
Time frame:
Cycle 1 Day 1 predose, Day 1 of Cycle 2 to Cycle 7, and end of treatment/discontinuation (assessed up to 1709 days)
Reported as:
Median · pg/mL
Plasma Concentration of Soluble Vascular Endothelial Growth Factor Receptor 3 (s-VEGFR3)
pg/mLAG-013736
Cycle 1 Day 1 (n=64)20250.0 (2060 to 132000)
Cycle 2 Day 1 (n=63)12000.0 (1990 to 45700)
Cycle 3 Day 1 (n=60)13100.0 (2090 to 47700)
Cycle 4 Day 1 (n=59)13800.0 (0 to 39100)
Cycle 5 Day 1 (n=57)16700.0 (0 to 38100)
Cycle 6 Day 1 (n=52)15550.0 (5200 to 39800)
Cycle 7 Day 1 (n=48)13750.0 (0 to 38200)
End of Treatment/Discontinuation (n=55)22300.0 (0 to 54500)
SecondaryPlasma Concentration of Soluble Stem Cell Factor Receptor (s-KIT)
Time frame:
Cycle 1 Day 1 predose, Day 1 of Cycle 2 to Cycle 7, and end of treatment/discontinuation (assessed up to 1709 days)
Reported as:
Median · pg/mL
Plasma Concentration of Soluble Stem Cell Factor Receptor (s-KIT)
pg/mLAG-013736
Cycle 1 Day 1 (n=64)39050.0 (24800 to 73700)
Cycle 2 Day 1 (n=63)35000.0 (21800 to 64000)
Cycle 3 Day 1 (n=60)37300.0 (20700 to 65000)
Cycle 4 Day 1 (n=59)38100.0 (20100 to 64300)
Cycle 5 Day 1 (n=57)39800.0 (24600 to 70700)
Cycle 6 Day 1 (n=52)41400.0 (23500 to 65900)
Cycle 7 Day 1 (n=48)42400.0 (23100 to 62000)
End of Treatment/Discontinuation (n=55)40600.0 (22200 to 72000)
SecondaryPlasma Concentration of Vascular Endothelial Growth Factor (VEGF)
Time frame:
Cycle 1 Day 1 predose, Day 1 of Cycle 2 to Cycle 7, and end of treatment/discontinuation (assessed up to 1709 days)
Reported as:
Median · pg/mL
Plasma Concentration of Vascular Endothelial Growth Factor (VEGF)
pg/mLAG-013736
Cycle 1 Day 1 (n=64)63.40 (26.4 to 361)
Cycle 2 Day 1 (n=63)162.00 (31.5 to 856)
Cycle 3 Day 1 (n=60)137.00 (26.3 to 723)
Cycle 4 Day 1 (n=59)145.00 (21.9 to 514)
Cycle 5 Day 1 (n=57)155.00 (24.3 to 554)
Cycle 6 Day 1 (n=52)184.50 (21.3 to 743)
Cycle 7 Day 1 (n=48)180.00 (46 to 762)
End of Treatment/Discontinuation (n=55)121.00 (15.6 to 617)
SecondaryNumber of Participants With Adverse Events

Number of participants with any adverse events, adverse events graded as Common Terminology Criteria (CTCAE) for Adverse Events Version 3.0 Grade 3 or higher , serious adverse events, or adverse events resulted in discontinuation.

Time frame:
Up to 1709 days of treatment plus 28-days follow-up
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsAG-013736
Any adverse events64
Any serious adverse events21
Any Grade-3 or -4 adverse events58
Any Grade-5 adverse events (= death)1
Discontinuation due to adverse events16

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AG-013736—21/64 (32.8%)64/64 (100%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventAG-013736
DiarrhoeaGastrointestinal disorders3/64
VomitingGastrointestinal disorders2/64
PneumoniaInfections and infestations2/64
DehydrationMetabolism and nutrition disorders2/64
HypertensionVascular disorders2/64
Acute myocardial infarctionCardiac disorders1/64
Angina unstableCardiac disorders1/64
Myocardial infarctionCardiac disorders1/64
HyperthyroidismEndocrine disorders1/64
Duodenal stenosisGastrointestinal disorders1/64
Most frequent other events
Showing 10 of 283
Most frequent other events
EventAG-013736
HypertensionVascular disorders56/64
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders48/64
DiarrhoeaGastrointestinal disorders44/64
FatigueGeneral disorders36/64
DysphoniaRespiratory, thoracic and mediastinal disorders34/64
ProteinuriaRenal and urinary disorders33/64
HypothyroidismEndocrine disorders31/64
Decreased appetiteMetabolism and nutrition disorders27/64
NasopharyngitisInfections and infestations25/64
NauseaGastrointestinal disorders22/64

Baseline characteristics

Age, Customized
Age, Customized(Participants)AG-013736
<180
18-446
45-6430
>= 6528
Sex: Female, Male
Sex: Female, Male(Participants)AG-013736
Female20
Male44
08

Study locations

18 sites
  • National Cancer Center East Hospital
    Kashiwa, Chiba 277-8577, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido 060-8648, Japan
  • Tsukuba University Hospital
    Tsukuba, Ibaraki 305-8576, Japan
  • Iwate Medical University
    Morioka, Iwate 020-8505, Japan
  • Kochi Medical School Hospital
    Nankoku-shi, Kochi-ken 783-8505, Japan
  • Kinki University Hospital
    Osakasayama, Osaka 589-8511, Japan
  • Hamamatsu University School of Medicine University Hospital
    Hamamatsu-City, Shizuoka 431-3192, Japan
  • Shizuoka Cancer Center
    Sunto-gun, Shizuoka 411-8777, Japan
  • Tokyo Women's Medical University Medical Center East
    Arakawa-ku, Tokyo 116-8567, Japan
  • National Cancer Center
    Chuo-ku, Tokyo 104-8503, Japan
  • Nihon University Itabashi Hospital
    Itabashi-ku, Tokyo 173-8610, Japan
  • Akita University Hospital
    Akita, 010-8543, Japan
  • National Kyushu Cancer Center
    Fukuoka, 811-1395, Japan
  • Kyushu University Hospital, Department of Urology
    Fukuoka, 812-8582, Japan
  • University Hospital, Kyoto Prefectural University of Medicine
    Kyoto, 602-8566, Japan
  • Osaka University Hospital
    Osaka, 565-0871, Japan
  • Tokushima University Hospotal
    Tokushima, 770-8503, Japan
  • Yamagata University Hospital
    Yamagata, 990-9585, Japan
09

References and documents

Publications

  • Schindler E, Amantea MA, Karlsson MO, Friberg LE. A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients. CPT Pharmacometrics Syst Pharmacol. 2017 Jun;6(6):373-382. doi: 10.1002/psp4.12193. Epub 2017 May 26. PubMed 28378918 ↗
  • Eto M, Uemura H, Tomita Y, Kanayama H, Shinohara N, Kamei Y, Fujii Y, Umeyama Y, Ozono S, Naito S, Akaza H; Japan Axitinib Phase II Study Group. Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma. Cancer Sci. 2014 Dec;105(12):1576-83. doi: 10.1111/cas.12546. Epub 2014 Nov 25. PubMed 25283266 ↗
  • Tomita Y, Uemura H, Fujimoto H, Kanayama HO, Shinohara N, Nakazawa H, Imai K, Umeyama Y, Ozono S, Naito S, Akaza H; Japan Axitinib Phase II Study Group. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer. 2011 Nov;47(17):2592-602. doi: 10.1016/j.ejca.2011.07.014. Epub 2011 Aug 31. PubMed 21889330 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2007 to primary completion in Feb 2010, 26 months.

Results were first posted in Mar 2012, 2 years 1 month after primary completion.

Of 47 industry-sponsored phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's 26 months is below that.

Counting every sponsor, half of 231 studies reached it within 59 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2007
First posted
Dec 10, 2007
StartActual
Dec 12, 2007
Primary completionActual
Feb 26, 2010
CompletionActual
Oct 30, 2012
Results first posted
Mar 27, 2012
Last update
Jun 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00569946
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 10, 2007
Start date
Dec 12, 2007
Primary completion
Feb 26, 2010
Completion
Oct 30, 2012
Results posted
Mar 27, 2012
Last update
Jun 5, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion